Skip to main content

Table 2 Transition probabilities for the first three cycles [18]

From: Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Model cycle

From response to

From no response to

Response

No response

Response

No response

1

0.000

0.000

0.539

0.461

2

0.843

0.157

0.278

0.722

3

0.878

0.122

0.248

0.752